-
Access to HealthcareCardiovascular DiseaseHeart DiseaseNovartis Access
-
More than 100,000 patients with heart failure in China are using our new AI-enabled platform, AI Nurse, to manage their condition and aim for better health.
DigitalReimagine MedicineCardiovascular DiseaseFuture of HealthcareAccess to Healthcare -
Reimagine MedicineInnovationCardiovascular DiseaseAd Hoc
-
Basel, March 18, 2020 — Novartis announced today the publication of three pivotal Phase III clinical trials for inclisiran, a potential first-in-class small interfering RNA (siRNA) investigational agent for hyperlipidemia in adults. The findings were published in two online articles ahead of print in The New England Journal of Medicine. The…Reimagine MedicineHeart DiseaseCardiovascular Disease
-
Basel, March 28, 2020 — Novartis today announced results from a prespecified analysis of pooled data from three Phase III studies evaluating the safety and efficacy of inclisiran, its first-in-class investigational treatment for hyperlipidemia in adults. The data was presented during a Late Breaker session at the American College of Cardiology’s…Reimagine MedicineInnovationCardiovascular Disease